Biotech Values

[AlpineBV_Miller]

I agree, but at least they are randomized. Mark Ratain, the arguable father of this trial design (or at least its biggest promoter) argues the enrichment is a byproduct but the important thing is tohave some randomization to help design the Phase III trials.

If you ever get a chance to chat with him about this design, it's worth the conversation. He's a great guy and one of the very few practicing clinicians (he's a hematologist) I've met who really understands statistics.